Both in Biotechnology
Silexion Therapeutics vs AIM ImmunoTech
Over the past year SLXN returned −99.6% and AIM returned −93.2%; their daily moves had a correlation of 0.01.
SLXN −99.6% AIM −93.2%Growth of $1, one year, split-adjusted
| Metric | SLXN | AIM |
|---|---|---|
| Price | $0.1423 | $0.1610 |
| Market cap | $2.1M | $6.4M |
| Today | −7.11% | −2.42% |
| 1 month | −48.7% | −8.0% |
| 6 months | −97.7% | −69.0% |
| Year to date | −99.3% | −85.7% |
| 1 year | −99.6% | −93.7% |
| Revenue growth (YoY) | — | +4.0% |
| Gross margin | — | 80.8% |
| Net margin | — | −26876.9% |
| P/E (TTM) | — | — |
| Price / sales | — | 67.6× |
| Net cash | — | $6.3M |
| Dividend yield | — | — |
| Volatility (60d) | 240.7% | 70.2% |
| Short % of float | 3.5% | 3.6% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).